close

Enter

Log in using OpenID

Atopic Dermatitis Treatment Market

embed
Towards the end of 2027, the market is expected to reach a valuation of US$ 23,992.3 Mn. This growth will be further driven by continuous research and drug development and the introduction of revised reimbursement policies.
Atopic Dermatitis Treatment Market to Reach a Valuation of U$ 23,992.3 Mn in Revenues by
2027-End
A new report from Future Market Insights reveals that global atopic dermatitis treatment market
revenue is set to expand at a CAGR of 12.8% over the forecast period (2017–2027). In recent years,
the prevalence of atopic dermatitis has increased to a great extent, leading to higher demand for its
treatment. In addition, the arrival of novel drugs and therapeutic options is also facilitating the
growth of the global atopic dermatitis treatment market. Towards the end of 2027, the market is
expected to reach a valuation of US$ 23,992.3 Mn. This growth will be further driven by
continuous research and drug development and the introduction of revised reimbursement policies.
The report, titled “Atopic Dermatitis Treatment Market: Global Industry Analysis 2012–2016 and
Opportunity Assessment 2017–2027” has also analysed the market by splitting it into regional
segments. The dominance of North America on the global atopic dermatitis treatment is expected to
remain throughout the assessment period. In 2016, the region’s dermatitis treatment market
accounted for a revenue share of 30%. The market in the region is anticipated to witness a CAGR of
16.0% to reach a valuation of US$ 10,384 Mn over 2027. Meanwhile, the market is Western Europe
will maintain its second position behind North America. Pharma companies in Europe are
concentrating on expanding their product portfolio by acquiring smaller companies specialised in
dermatology portfolios. The report also projects a considerable growth of the atopic dermatitis
treatment market in Asia pacific excluding Japan (APEJ) over the next couple of years.
By drug class, corticosteroids currently account for the largest revenue share of the market.
However, biologic therapy and PDE-4 inhibitor are expected to outsell corticosteroids by the end of
forecast period.
Biologic therapy is projected to account for around 36.4% share of the market over 2027, expanding
at a CAGR of 26.4%. During the same period, the revenue share of PDE-4 inhibitor is expected to
expand at a staggering CAGR of 33.4%.
Request for Table of Contents @
https://www.futuremarketinsights.com/toc/rep-gb-3097
In 2017 and beyond, preference for drug administration using topical procedures will remains
significantly high as compared to oral and injectable administration modes. Topical drug
administration will account for more than two-third share of the market by 2027-end.
Hospital pharmacies remain the leading distribution channel despite the rapid proliferation of
dermatology clinics. In 2017, hospital pharmacy will represent a market share of 33.1%, which will
incur a slight downtrend and settle for 31.4% by the end of 2027.
Some of the leading pharmaceutical companies that have an active participation in the global atopic
dermatitis treatment market include: Sanofi SA, Galderma SA, Allergan Plc., Novartis, BristolMyers Squibb, Bayer AG, Meda Pharmaceuticals, Astellas Pharma Inc., Anacor Pharmaceutical
Inc., Regeneron Pharmaceuticals, Aqua Pharmaceuticals (An Almirall Company), Pfizer, Dow
Pharm, Connetics Corporation, Fujisawa Healthcare, Encore Dermatology, LEO Pharma, Velite
Pharmaceutical, Biofrontera AG.
Many of these market players are implementing strategies such as merger and acquisition in order
to enhance their product portfolio. At the same time, increasing numbers collaborations among
market players and medical research institutes are leading to new product development.
Buy Atopic Dermatitis Treatment Market Report @
https://www.futuremarketinsights.com/checkout/3097
Author
ashutosh
ashutosh164   documents Email
Document
Category
Health and Medicine
Views
4
File Size
36 KB
Tags
treatment, Atopic Dermatitis Treatment Market
1/--pages
Report inappropriate content